NDAORALTABLET
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
15/100
Clinical Trials
21
Data completeness
5/8 — Partial
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INVOKANA (canagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved in 2013 for type 2 diabetes management. It works by enabling the kidneys to remove excess glucose through urine, reducing blood sugar levels. The drug is administered orally as a tablet and represents a distinct mechanism of action within the diabetes therapeutic landscape.
$0.357BPart D
LOE Approaching2.9 years to LOEProduct is in peak-to-decline transition with 3 years to loss of exclusivity; commercial teams are pivoting toward lifecycle extension and managed transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Canagliflozin With Gemcitabine in Pancreatic Carcinoma
Started Oct 2023
20 enrolled
Pancreatic Cancer
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
Started Nov 2020
276 enrolled
Diabetes Mellitus
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
Started Mar 2020
476 enrolled
Heart Failure
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Started Sep 2018
178 enrolled
Diabetes Mellitus, Type 2
Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)
Started May 2018
0Type2 DiabetesHeart Failure
Worked on INVOKANA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.